Is your small business in need of financing to support the development of its innovative cancer research? Don’t miss out on two special funding opportunities from The National Cancer Institute Small Business Innovation Research
(NCI SBIR) Development Center: The FY2015 Contract Topics and the SBIR Innovative Molecular Analysis Technology (IMAT) Development for Cancer Research and Clinical Care.
Applications for both of these funding opportunities are due in early November. Review the opportunities below and apply today!
NCI SBIR Contract Topics Funding Opportunities
Due date: November 5, 2014 by 4:30 p.m. ET
The PHS 2015-1 solicitation includes the following contract topics for qualified small businesses to help advance the research, development, and commercialization of cancer research and technology in priority areas:
- 334 Vacutubes to Preserve the Viability of Circulating Tumor Cells
- 335 Development of Advanced Culture Systems for Expansion of Cancer Stem Cells
- 336 Development of Novel Therapeutic Agents That Target Cancer Stem Cells
- 337 Cell-Free Nucleic Acid-Based Assay Development for Cancer Diagnosis
- 338 Predictive Biomarkers of Adverse Reactions to Radiation Treatment
- 339 Systemic Targeted Radionuclide Therapy For Cancer Treatment
- 340 Validation of Mobile Technologies for Clinical Assessment, Monitoring, and Intervention
If you have questions about any of the topics or general questions on contract administration, please contact:
Ms. Victoria Cunningham
Please include Solicitation PHS 2015-1 and the Topic Number when submitting questions.
NCI SBIR Funding Opportunity: Innovative Molecular Analysis Technology Development for Cancer Research and Clinical Care
Next due date: November 4, 2014
The SBIR-IMAT solicitation is a companion announcement to the NCI Innovative Molecular Analysis Technologies (IMAT) Program aimed at the inception, development, integration, and application of novel and emerging technologies in support of cancer research.
This solicitation will provide small businesses the opportunity to advance technologies that improve molecular and/or cellular analysis of cancer with a significant likelihood for either overcoming persistent challenges or obstacles or opening entirely new fields for cancer research or clinical care. View the presentation slides from the latest webinar on SBIR-IMAT.
To view the full SBIR-IMAT FOA, please visit:
PAR-13-327, Innovative Molecular Analysis Technology Development for Cancer Research and Clinical Care (R43/R44)
For more information or questions on the SBIR-IMAT funding opportunity, please contact:
Amir Rahbar, PhD, MBA
Program Director, NCI SBIR
Announcements from NIH: Resources for Small Business Applicants
NIH recently announced the Niche Assessment Program, which provides SBIR and STTR Phase I awardees with a free comprehensive market analysis report that can help jump start commercialization efforts for small businesses. Applications are accepted on a first-come, first served basis until all 136 slots are filled. Learn more and apply! Be sure to continue to check our website for updates and events. For a full list of funding opportunities currently available from the NCI SBIR & STTR Programs, please visit the Funding Receipt Dates page.The SBIR & STTR Programs are NCI’s engine of innovation for developing and commercializing novel technologies and products to prevent, diagnose, and treat cancer. The SBIR & STTR Programs are government set-aside programs for domestic small businesses to engage in research and development that has the potential for commercialization and public benefit.
Sign up to receive updates about
SBIR & STTR funding opportunities at
Want to Receive NCI Updates in your E-Mailbox – please subscribe.
|Follow NCI on Twitter||Connect with NCI on LinkedIn|